Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Issues related to drug pricing, value, and transparency, generally
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Tax issues related to supply chain; Puerto Rico
Duration: January 11, 2017
to
present
General Issues: Medicare/Medicaid , Health Issues , Taxation/Internal Revenue Code , Pharmacy
Spending: about $1,350,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2017: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Steven Irizarry Counsel, House Energy & Commerce Committee; Counsel, Senate Special Committee on Aging; Counsel, Senate HELP; Counsel, Senator Chuck Hagel
Counsel, House Energy & Commerce Committee; Counsel, Senate Special Committee on Aging; Counsel, Senate HELP; Counsel, Senator Chuck Hagel
Israel "Izzy" Klein Deputy Staff Director, Joint Economic Committee, Chairman Chuck Schumer; Senior Communications Advisor, Representative Ed Markey; Communications Director, Senator Chuck Schumer; Press Secretary and Legislative Assistant, Representative Ed Markey
Steve Irizarry Counsel, House Energy & Commerce Committee; Counsel, Senate Special Committee on Aging; Counsel, Senate HELP; Counsel, Senator Chuck Hagel
Vincent Roberti Sr n/a
Vincent Roberti Sr. n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Roberti Global (fka Roberti White, LLC) did no lobbying for AMGEN . The report was filed on April 21.
Original Filing: 301569335.xml
4th Quarter, 2023
In Q4, Roberti Global (fka Roberti White, LLC) did no lobbying for AMGEN . The report was filed on Jan. 21.
Original Filing: 301534966.xml
3rd Quarter, 2023
In Q3, Roberti Global (fka Roberti White, LLC) did no lobbying for AMGEN . The report was filed on Oct. 18, 2023.
Original Filing: 301505058.xml
2nd Quarter, 2023
In Q2, Roberti Global (fka Roberti White, LLC) did no lobbying for AMGEN . The report was filed on July 18, 2023.
Original Filing: 301478937.xml
1st Quarter, 2023
In Q1, Roberti Global (fka Roberti White, LLC) did no lobbying for AMGEN . The report was filed on April 20, 2023.
Original Filing: 301461740.xml
4th Quarter, 2022
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $30,000. The report was filed on Jan. 18, 2023.
Original Filing: 301430294.xml
Lobbying Issues
Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to supply chain; Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $30,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415762.xml
Lobbying Issues
Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Coding and reimbursement for oncology drugs/biologics/biosimilars
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to supply chain; Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $30,000. The report was filed on July 19, 2022.
Original Filing: 301387273.xml
Lobbying Issues
Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Coding and reimbursement for oncology drugs/biologics/biosimilars
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues related to International Pricing Index; Most Favored Nation drug pricing
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to supply chain; Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on April 17, 2022.
Original Filing: 301357919.xml
Lobbying Issues
Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Coding and reimbursement for oncology drugs/biologics/biosimilars
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues related to International Pricing Index; Most Favored Nation drug pricing
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to supply chain; Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331226.xml
Lobbying Issues
Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Coding and reimbursement for oncology drugs/biologics/biosimilars
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues related to International Pricing Index; Most Favored Nation drug pricing
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to supply chain; Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301307806.xml
Lobbying Issues
Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Coding and reimbursement for oncology drugs/biologics/biosimilars
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues related to International Pricing Index; Most Favored Nation drug pricing
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to supply chain; Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301287348.xml
Lobbying Issues
Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Coding and reimbursement for oncology drugs/biologics/biosimilars
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues related to International Pricing Index; Most Favored Nation drug pricing
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to supply chain; Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on April 19, 2021.
Original Filing: 301258236.xml
Lobbying Issues
Issues related to Medicare Part B coverage and reimbursement, generally
Issues related to Medicare Part D, generally
Coding and reimbursement for oncology drugs/biologics/biosimilars
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues related to International Pricing Index; Most Favored Nation drug pricing
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to supply chain; Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Jan. 20, 2021.
Original Filing: 301239303.xml
Lobbying Issues
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues relating to the 340B Drug Pricing Program
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
Roberti Global (fka Roberti White, LLC) amended a lobbying report for representation of AMGEN in Q42020 on Jan. 20, 2021.
Original Filing: 301239376.xml
Lobbying Issues
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues relating to the 340B Drug Pricing Program
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Oct. 19, 2020.
Original Filing: 301214490.xml
Lobbying Issues
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues relating to the 340B Drug Pricing Program
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2020
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301201215.xml
Lobbying Issues
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues relating to the 340B Drug Pricing Program
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax issues related to Puerto Rico
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301175465.xml
Lobbying Issues
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Issues relating to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues relating to the 340B Drug Pricing Program
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124763.xml
Lobbying Issues
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Issues relating to the 340B Drug Pricing Program
Transitional drug add-on payment (TDAPA)i
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues relating to the 340B Drug Pricing Program
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078227.xml
Lobbying Issues
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Issues relating to the 340B Drug Pricing Program
Transitional drug add-on payment (TDAPA)i
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues relating to the 340B Drug Pricing Program
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301056191.xml
Lobbying Issues
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Issues relating to the 340B Drug Pricing Program
Transitional drug add-on payment (TDAPA)i
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing, value, and transparency, generally
Issues related to the importation of prescription medicines
Issues relating to the 340B Drug Pricing Program
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301038662.xml
Lobbying Issues
Medicare Part B coverage and reimbursement issues
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Issues relating to the 340B Drug Pricing Program
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015888.xml
Lobbying Issues
Issues related to Medicare Part B
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Issues relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); the Ensuring the Value of the 340B Program Act (S. 2453), and the 340B Optimization Act (H.R. 5598)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Oct. 22, 2018.
Original Filing: 300997794.xml
Lobbying Issues
Issues related to Medicare Part B
Issues related to Medicare Part D
Coding and reimbursement for oncology drugs/biologics/biosimilars
Issues relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); the Ensuring the Value of the 340B Program Act (S. 2453), and the 340B Optimization Act (H.R. 5598)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Puerto Rico tax incentives
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
Issues related to drug pricing and value, generally
Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300977106.xml
Lobbying Issues
- Issues related to Medicare Part B (Average Sales Price)
- Issues related to Medicare Part D
- Coding and reimbursement for oncology drugs/biologics/biosimilars
- Issues relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); the Ensuring the Value of the 340B Program Act (S. 2453), and the 340B Optimization Act (H.R. 5598)
- Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Puerto Rico tax incentives
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
- Issues related to drug pricing and value, generally
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300956851.xml
Lobbying Issues
- Issues related to Medicare Part B included in the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625)
- Issues related to Medicare Part D included in the Bipartisan Budget Act (H.R. 1892); and the Consolidated Appropriations Act (H.R. 1625)
- Issues related to the repeal of the Independent Payment Advisory Board (IPAB); Protecting Seniors' Access to Medicare Act of 2017 (H.R. 849/S. 260); Protecting Medicare from Executive Action Act of 2017 (S. 251)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Puerto Rico tax incentives
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issued relating to the 340B Drug Pricing Program, including the 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act (H.R. 4710); the Helping Ensure Low-income Patients have Access to Care and Treatment (HELP) Act (S. 2312); and the Ensuring the Value of the 340B Program Act (S. 2453)
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
- Issues related to biosimilars, generally; Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974/H.R. 2212)
- Issues related to drug pricing and value, generally
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300933029.xml
Lobbying Issues
- Issues related to Medicare Part B (Average Sales Price) and Part D (rebates)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- International corporate tax reform; Puerto Rico tax incentives
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- American Health Care Act (H.R. 1628) and Better Care Reconciliation Act
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA)
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300914418.xml
Lobbying Issues
- Issues related to Medicare Part B (Average Sales Price) and Part D (rebates)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- International corporate tax reform; Puerto Rico tax incentives
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- FDA Reauthorization Act (H.R. 2430/S. 934)
- American Health Care Act (H.R. 1628) and Better Care Reconciliation Act
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300894081.xml
Lobbying Issues
- Issues related to Medicare Part B (Average Sales Price) and Part D (rebates)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- International corporate tax reform; Puerto Rico tax incentives
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- FDA Reauthorization Act (H.R. 2430/S. 934)
- American Health Care Act (H.R. 1628) and Better Care Reconciliation Act
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Roberti Global (fka Roberti White, LLC) lobbied for AMGEN , earning $60,000. The report was filed on April 20, 2017.
Original Filing: 300876478.xml
Lobbying Issues
- Legislation repealing and replacing the Affordable Care Act, including the American Health Care Act (H.R. 1628)
Agencies Lobbied
U.S. Senate
Lobbying Issues
- Reimbursement issues related to Medicare Part B and Part D
- Coding and reimbursement for oncology drugs/biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
- International corporate tax reform
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
- Issues relating to the 340B Drug Pricing Program
- Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), including reauthorization of the Prescription Drug User Fee Act (PDUFA VI)
- Issues related to biosimilars, generally
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
Roberti Global (fka Roberti White, LLC) filed a lobbying registration on Feb. 13, 2017 to represent AMGEN, effective Jan. 11, 2017.
Original Filing: 300860320.xml
Issue(s) they said they’d lobby about: - Federal Food, Drug and Cosmetic Act
- FDA reform
- Reauthorization of FDA prescription drug and biosimilar user fee programs
- Biosimilars, generally
- Reimbursement issues related to Medicare Part B and Part D
- Coding and reimbursement for oncology drugs/biologics
- International Tax reform .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...